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Abstract
Background: We investigated the differential regulation of p-p38 MAPK or p-NF-B in male Sprague-Dawley rats
with inferior alveolar nerve injury resulting from mal-positioned dental implants. For this purpose, we characterized
the temporal expression of p-p38 MAPK or p-NF-B in the medullary dorsal horn and examined changes in
nociceptive behavior after a blockade of p-p38 MAPK or p-NF-B pathways in rats with trigeminal neuropathic pain.
Results: Under anesthesia, the left lower second molar was extracted and replaced with a mini dental implant to
intentionally injure the inferior alveolar nerve. Western and immunofluorescence analysis revealed that p-p38 MAPK
is upregulated in microglia following nerve injury and that this expression peaked on postoperative day (POD) 3
through 7. However, the activation of p-NF-B in astrocyte peaked on POD 7 through 21. The intracisternal
administration of SB203580 (1 or 10 μg), a p38 MAPK inhibitor, on POD 3 but not on POD 21 markedly inhibits
mechanical allodynia and the p-p38 MAPK expression. However, the intracisternal administration of SN50 (0.2 or 2
ng), an NF-B inhibitor, on POD 21 but not on POD 3 attenuates mechanical allodynia and p-NF-B expression.
Dexamethasone (25 mg/kg) decreases not only the activation of p38 MAPK but also that of NF-B on POD 7.
Conclusions: These results suggest that early expression of p-p38 MAPK in the microglia and late induction of p-
NF-B in astrocyte play an important role in trigeminal neuropathic pain and that a blockade of p-p38 MAPK at an
early stage and p-NF-B at a late stage might be a potential therapeutic strategy for treatment of trigeminal
neuropathic pain.
Background
Injuries of the peripheral nerve often result in neuro-
pathic pain, which is characterized by allodynia, hyperal-
gesia or spontaneous pain. These injuries may affect the
activity of spinal glial cells, which are involved in the
pathogenesis of neuropathic pain [1]. The spinal glial
cells, mainly comprising microglia and astrocyte, are
also the most abundant immune cells in the central ner-
vous system. Following peripheral nerve damage, resting
microglia and astrocyte are converted to an activated
state through a series of cellular and molecular changes
[2,3]. In addition, activated microglia and astrocyte par-
ticipate in the release of pro-inflammatory cytokines
such as interleukin-1 beta (IL-1b), interleukin-6 (IL-6),
or tumor necrosis factor-alpha (TNF-a), which may
augment nociceptive signaling in the spinal cord [4].
Recently, p38 mitogen-activated protein kinase (p38
MAPK) was found to contribute to neuropathic pain in
several animal models. Intrathecal injections of p38
MAPK inhibitors were shown to reverse mechanical
allodynia and thermal hyperalgesia in rats with an L5
spinal nerve ligation [5]. In addition, the activation of
microglial p38 MAPK following an L5 spinal nerve
transaction is reduced by minocycline, a microglia inhi-
bitor, or SB203580, a p38 MAPK inhibitor [6]. Emerging
evidence also now indicates that the activation of
nuclear factor kappa B (NF-B) following nerve injury is
related to the generation of neuropathic pain. Spinal
nerve ligation increases the expression of phospho-NF-
B (p-NF-B) in astrocyte and this activated NF-B par-
ticipates in tactile allodynia [7]. Intrathecal pretreatment
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by sciatic inflammatory neuropathy [8] and L5 ventral
root transaction [9]. However, although the accumulat-
ing evidence from diverse animal models indicates that
the activation of p38 MAPK and NF-B plays an impor-
tant role in neuropathic pain, it remains unknown
whether these molecules contribute to the development
or modulation of behavioral responses in trigeminal
neuropathic pain.
Recently, Han et al. reported that inferior alveolar
nerve injury induced by the mal-positioning of dental
implants produces prolonged mechanical allodynia in
the trigeminal territory in rats [10]. In our present
study, we investigated the differential regulation of phos-
pho-p38 (p-p38) MAPK and p-NF-Bi nt h i ss a m er a t
model. We examined changes in temporal expression of
p-p38 MAPK and p-NF-Bi nt h em e d u l l a r yd o r s a l
horn and also evaluated nociceptive behavior in the sub-
ject animals following a blockade of p38 MAPK and
NF-B activation. In addition, we investigated whether
the p38 MAPK or NF-B pathways participate in the
antinociceptive action of dexamethasone.
Results
Differential expression of p-p38 MAPK and p-NF-B
Figure 1 illustrates changes in temporal expression of p-
p38 MAPK and p-NF-B in the medullary dorsal horn
in rats after the inferior alveolar nerve injury produced
by the placement of mal-positioned dental implants.
The sham-treated rats did not show any changes in the
expression of these factors as compared to the naïve
group (data not shown). However, the expression of p-
Figure 1 Changes in temporal expression of p-p38 MAPK and p-NF-B. The expression of p-p38 MAPK and p-NF-B is increased in the rat
medullary dorsal horn after inferior alveolar nerve injury induced by mal-positioned dental implants (A). The levels of p-p38 MAPK peaked on
POD 3 and 7 and those of p-NF-B peaked on POD 7 and 21, compare to the naïve group. Western blotting analysis showed the early
activation of p38 MAPK and late activation of NF-B (B). Quantitative analysis of western blotting results revealed that p-p38 MAPK expression
increases significantly on POD 3 and 7 and that p-NF-B expression is markedly upregulated on POD 7 and 21 compared to the naïve group (C).
*P < 0.05, naive- vs. nerve injured- group. Scale bars, 200 μm
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on postoperative day (POD) 3 and was maintained at
this level by POD 7 when compared to the naïve group.
Unlike p-p38 MAPK, however, the p-NF-Bp e a k e do n
POD 7 and persisted on POD 21 (Figure 1A). Western
blotting analysis confirmed that the increases in the
phosphorylation of p38 MAPK and NF-B are time-
dependent following nerve injury. Significant increases
in the expression of p-p38 MAPK on POD 3 through
POD 7 and p-NF-Bo nP O D7t h r o u g hP O D2 1w e r e
detected by immunoblotting when compared to the
naïve group (P < 0.05; Figure 1B, 1C).
Effects of treatment with SB203580
The effects of SB203580 treatments on mechanical allo-
dynia in rats with trigeminal neuropathic pain induced
by inferior alveolar nerve injury are illustrated in Figure
2. The intracisternal administration of SB203580 (1 or
10 μg), a p38 MAPK inhibitor, inhibited mechanical
allodynia in a dose-dependent manner when it was
administered on POD 3 (F(2, 18) = 34.056, P < 0.001).
These anti-allodynic responses persisted for six hours
and recovered within 24 hours. Mirror image mechani-
cal allodynia was also attenuated by the intracisternal
administration of SB203580. However, intracisternally
injected SB203580 did not alter the air-puff threshold
when it was administered on POD 21 (Figure 2A). On
POD 3, the intracisternal administration of SB203580
(10 μg) significantly reduced p-p38 MAPK expression in
the ipsilateral medullary dorsal horn as compared to the
vehicle group (Figure 2B). Western blotting analysis also
revealed the inhibition of p38 MAPK phosphorylation
after treatment with SB203580 (Figure 2C).
Effects of SN50
The effects of treatment with SN50 on mechanical allo-
d y n i ai no u rr a tm o d e la r es h o w ni nF i g u r e3 .T h ei n t r a -
cisternal administration of SN50 (0.2 or 2 ng) on POD 21
but not on POD 3 produced significant anti-allodynic
effects compared to the vehicle group (F(2, 18) = 21.185, P
< 0.001). These anti-allodynic responses persisted for six
hours and recovered within 24 hours. Mirror image
mechanical allodynia was also attenuated by SN50 in this
experiment (Figure 3A). On POD 21, the intracisternal
administration of SN50 (2 ng) significantly reduced p-
NF-kB expression in the ipsilateral medullary dorsal horn
as compared to the vehicle group (Figure 3B). Western
blotting analysis confirmed the inhibition of NF-kB phos-
phorylation after treatment with SN50 (Figure 3C).
Co-localization of p-p38 MAPK and p-NF-kB
We performed double immunostaining for p-p38 MAPK
on POD 3 and p-NF-B on POD 21 (Figure 4, 5). The
results revealed that p-p38 MAPK co-localizes with
OX42, a marker of microglia, but not with neuronal
nuclei (NeuN), a neuronal marker or glial fibrillary acidic
protein (GFAP), an astrocyte marker, in the medullary
dorsal horn (Figure 4). In contrast, most of the p-NF-B
immunoreactive cells were found to co-localize with
GFAP in the medullary dorsal horn (Figure 5).
Effects of dexamethasone on p-p38 MAPK and p-NF-B
expression
We recently demonstrated that the early administration
of dexamethasone significantly blocks mechanical allo-
dynia and hyperalgesia produced by mal-positioned den-
tal implants [10]. To evaluate in our current study
whether the antinociception produced by dexametha-
sone is associated with p38 MAPK or NF-B phosphor-
ylation, we performed immunostaining following the
intraperitoneal administration of 25 mg/kg of dexa-
methasone in rats with trigeminal neuropathic pain. The
systemic administration of dexamethasone significantly
attenuated mechanical allodynia produced by mal-posi-
tioned dental implants (data not shown). Dexametha-
sone also attenuated the increased p-p38 MAPK in the
medullary dorsal horn on POD 7, compared to the vehi-
cle-treated group, when administered intraperitoneally
once daily for three consecutive days beginning on POD
1 (Figure 6A). Moreover, dexamethasone treatment sig-
nificantly reduced the expression of p-NF-Bi nt h e
medullary dorsal horn on POD 7 compared with the
vehicle-treated group (Figure 6B). Western blotting ana-
lysis further confirmed the attenuation of p38 MAPK
and NF-B phosphorylation following treatment with
dexamethasone (P < 0.05).
Discussion
The results of our present study demonstrate that mal-
positioned dental implants significantly increase the
early phosphorylation of p38 MAPK in microglia and
late phosphorylation of NF-B in astrocyte. On POD 3,
the intracisternal administration of SB203580 signifi-
cantly inhibited both mechanical allodynia and the
expression of p-p38 MAPK. On POD 21, the intracister-
nal administration of SN50 significantly inhibited both
mechanical allodynia and the expression of p-NF-B.
Moreover, treatment with dexamethasone, which pro-
duces potent anti-nociceptive effects, significantly atte-
nuated the expression of p-p38 MAPK and p-NF-Bi n
rats with inferior nerve injury produced by mal-posi-
tioned dental implants. These results suggest that the
activation of p38 MAPK and NF-B play a critical role
in the development and maintenance of trigeminal neu-
ropathic pain.
Previous studies have reported that chronic constric-
tion injury of the infraorbital nerve or inferior alveolar
nerve damage produces abnormal nociceptive behavior
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Page 3 of 11Figure 2 Antinociceptive effects of SB203580, a p38 MAPK inhibitor. Effects of SB203580 on mechanical allodynia in rats with trigeminal
neuropathic pain produced by mal-positioned dental implants (A). The intracisternal administration of SB203580 (1 or 10 μg) inhibited
mechanical allodynia on the ipsilateral (left) and contralateral side (right) on POD 3 in a dose-dependent manner. These anti-allodynic responses
persisted for six hours and were recovered within 24 hours. On POD 21 however, SB203580 did not produce anti-nociceptive effects (lower
panel). The intracisternal administration of SB203580 (10 μg) attenuated p38 MAPK activation on POD 3 following inferior alveolar nerve injury as
compared to the vehicle group (B). Western blotting analysis showed decreases in p-p38 MAPK expression following the injection of SB203580
as compared to the vehicle treatment (C). *P < 0.001, vehicle- vs. SB203580-treated group. Scale bars, 50 μm.
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Page 4 of 11Figure 3 Antinociceptive effects of SN50, an NF-B inhibitor. Effects of SN50 on mechanical allodynia produced by mal-positioned dental
implants in rats (A). On POD 3, SN50 did not produce anti-nociceptive effects (upper panel). The intracisternal administration of SN50 (0.2 or 2
ng) inhibits mechanical allodynia on the ipsilateral (left) and contralateral side (right) on POD 21 in a dose-dependent manner. These anti-
allodynic responses persist for six hours and are recovered within 24 hours. The intracisternal administration of SN50 (2 ng) attenuates NF-B
activation on POD 21 following inferior alveolar nerve injury as compared to the vehicle group (B). Western blotting analysis showed decreases
in p-NF-B expression following injection of SN50 as compared to the vehicle treatment (C). *P < 0.001, vehicle- vs. SN50-treated group. Scale
bars, 50 μm.
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Page 5 of 11in the trigeminal region [11-15]. These nociceptive
behaviors, including allodynia, are similar to the symp-
toms of patients with neuropathic pain caused by nerve
injury. Dental implantation, one of the most common
prosthetic treatments, often results in injuries to the
nerve including the inferior alveolar or mental nerve.
Han et al. have previously described a novel animal
model for trigeminal neuropathic pain, which was pro-
duced by mal-position dental implants [10]. In our pre-
sent study, we used this animal model and found that it
produced severe long-lasting nociceptive behavior in the
ipsilateral and contralateral sides compare to the naïve
or sham groups. Accordingly, these results suggest that
this is an appropriate animal model for the clinical
study of trigeminal neuropathic pain. However, the
underlying cellular mechanisms involved in the develop-
ment and maintenance of trigeminal neuropathic pain
remain unclear.
P38 MAPK, one of the families of intracellular signal-
ing molecules that transduce extracellular responses,
plays an important role in the development and mainte-
nance of nerve injury-induced pain hypersensitivity [16].
Emerging evidence now indicates that activated p38
MAPK is involved in the development of neuropathic
pain after nerve injury. The activation of p38 MAPK has
been previously observed in the spinal cord following
spinal nerve injury [17-19], spared nerve injury [20], and
spinal cord injury [21]. Moreover, the intrathecal
administration of a p38 MAPK inhibitor prevents the
generation of neuropathic pain in rats with nerve injury
[17,18,20,22]. In our present study, the intracisternal
administration of SB203580 on POD 3 significantly
inhibited mechanical allodynia induced by mal-posi-
tioned dental implants. On POD 21 however, SB203580
did not affect mechanical allodynia. This early role of
p38 MAPK is consistent with the findings of a previous
s t u d ys h o w i n gt h a tt h ep 3 8M A P Kl e v e l sr a p i d l y
increase and reached a peak at three days after nerve
injury [17]. The results of our present study also show
that an inferior alveolar nerve injury markedly induces
an increase in p-p38 MAPK expression on POD 3 and
7. Moreover, p38 MAPK immunoreactive cells were
found to co-localize with OX42 but not with NeuN or
GFAP. These results, taken together with our behavioral
analysis, suggest that a blockade of early p38 MAPK
expression in microglia may be a potential therapeutic
strategy for the treatment of trigeminal neuropathic
pain.
Similarly to p38 MAPK, NF-Bi sa l s oi n v o l v e di n
environmental stress-responsive pathways, including
those that are activated by inflammatory insults [23].
Recent studies also indicate that NF-Bi si n v o l v e di n
the pathogenesis of neuropathic and inflammatory pain
[24-26]. NF-B is activated in dorsal root ganglia follow-
ing partial sciatic nerve injury [27] and in the dorsal
horn following spinal nerve ligation [7]. The results of
our present study demonstrate that the expression of p-
Figure 4 Double immunofluorescent staining of p-p38 MAPK.
P-p38 MAPK (red) immunoreactive cells were found to mainly co-
localize with OX42 (green), but not NeuN (green) or GFAP (green) in
the rat medullary dorsal horn following inferior alveolar nerve injury.
Scale bars, 50 μm.
Figure 5 Double immunofluorescent staining of p-NF-kB.A l lp -
NF-kB (red) immunoreactive cells co-localize with GFAP (green), but
not NeuN (green) or OX42 (green) in the rat medullary dorsal horn
following inferior alveolar nerve injury. Scale bars, 50 μm.
Lee et al. Molecular Pain 2011, 7:57
http://www.molecularpain.com/content/7/1/57
Page 6 of 11Figure 6 Effects of dexamethasone on the expression of p-p38 MAPK and p-NF-B. The intraperitoneal administration of dexamethasone
(25 mg/kg) attenuates p-p38 MAPK expression on POD 7 following inferior alveolar nerve injury as compared to the vehicle group (A). Western
blotting analysis also revealed a significant decrease in p-p38 MAPK expression as compared to the vehicle treatment. The intraperitoneal
administration of dexamethasone (25 mg/kg) also attenuates p-NF-B expression on POD 7 following inferior alveolar nerve injury as compare to
the vehicle group (B). Western blotting analysis also confirmed this significant decrease in p-NF-B expression. *P < 0.05, vehicle- vs. drug-treated
group. Scale bars, 50 μm.
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on POD 7 and 21. The intracisternal injection of SN50,
an NF-B inhibitor, was found to attenuate the expres-
sion of p-NF-B as well as mechanical allodynia on
POD 21, but not on POD 3. Moreover the p-NF-B
immunoreactive cells were found to co-localize with
GFAP but not with NeuN or OX42. These results sug-
gest that the activation of NF-B in astrocyte, produced
by mal-positioned dental implants, play an important
role in the maintenance of trigeminal neuropathic pain.
This suggested role of NF-Bi na s t r o c y t ei nt h el a t e
stages of neuropathic pain is consistent with the results
of previous studies. NF-B has been shown in an earlier
report to mainly co-localize with GFAP [28,29] and the
activation of NF-B in nerve injury models has pre-
viously been demonstrated to occur in the later stages
of neuropathic pain [7,30]. These results, taken together
with our current behavioral analysis, suggest that a
blockade of NF-B in astrocyte may be a potential
future therapy for already established trigeminal neuro-
pathic pain.
Spinal glial cells, mainly microglia and astrocyte, play
an important role in innate immunity and after periph-
eral nerve injury are converted to an activated state
through a series of cellular and molecular changes [2,3].
Recent studies have also indicated that activated micro-
glia and astrocyte play important roles in the develop-
ment and maintenance of neuropathic pain caused by
nerve injury [7,13,17,31]. Following nerve injury, acti-
v a t e dm i c r o g l i aa n da s t r o c y te release a variety of pro-
inflammatory cytokines, such as IL-1b,I L - 6 ,o rT N F - a,
which may augment the nociceptive signals in the spinal
cord [4]. Moreover, treatment with specific inhibitors of
microglia or astrocyte significantly attenuates nociceptive
responses following nerve injury [3]. In addition, micro-
glial activation following nerve injury increases in the
spinal dorsal horn within several hours [32] whereas
astrocyte activation seems to initiate several days after
nerve injury [7,31]. However, there is no direct behavioral
evidence for the differential regulation of glial cells in rats
with trigeminal neuropathic pain. Our current analyses
demonstrate that an early blockade of p38MAPK in
microglia and a late blockade of NF-B in astrocyte sig-
nificantly attenuate mechanical allodynia following infer-
ior alveolar nerve injury. These results suggest that nerve
injuries produce a differential activation of spinal glial
cells which may contribute to the development or main-
tenance of trigeminal neuropathic pain.
Previous reports have demonstrated that glucocorti-
coids attenuate nociceptive behavior in neuropathic pain
animal models [33,34] and inhibit the development and
maintenance of neuropathic pain [35]. Recently, Han et
al. reported that early treatment with dexamethasone
produces a prolonged inhibition of mechanical allodynia
in a rat model of trigeminal neuropathic pain produced
by mal-positioned dental implants [10]. Daily treatment
with dexamethasone significantly reduced the expression
of p-p38 MAPK and p-NF-Bo nP O D7i no u rp r e s e n t
experiments. Taken together, these results indicate that
dexamethasone produces anti-allodynic effects through
the inhibition of p38 MAPK and NF-B activation.
Conclusions
Our results indicate that the nerve injury produced by
mal-positioned dental implants in rats significantly aug-
ments the early activation of p38 MAPK in the microglia
and the late activation of NF-B in astrocyte. Early treat-
ment with SB203580, a p38 MAPK inhibitor, and late
treatment with SN50, an NF-Bi n h i b i t o r ,a t t e n u a t e s
nociceptive behavior. The antinociceptive effects of dexa-
methasone are mediated by a blockade of both p38
MAPK and NF-B activation. These data suggest that the
early blockade of p38 MAPK or late inhibition of NF-B
is potential therapeutic approaches to the treatment of
trigeminal neuropathic pain produced by dental implants.
Methods
Animals and Surgery
Male Sprague-Dawley rats (220-250 g) were used in this
study. The animals were anesthetized with 5% isoflurane
in oxygen and maintained with 2% during surgery. Under
this anesthesia, the left lower second molar was extracted
and replaced with a mini dental implant (diameter, 1
mm; length, 4 mm; donated by Megagen, Gyengsan,
Korea) to intentionally injure the inferior alveolar nerve
as described previously [10]. A sham group was operated
on without performing the dental implant placement. All
procedures involving the use of animals were approved
by the Institutional Care and Use Committee of the
School of Dentistry, Kyungpook National University and
were carried out in accordance with the ethical guidelines
for the investigation of experimental pain in conscious
animals of the International Association for the Study of
Pain. The animals were maintained in a temperature-
controlled room (23 ± 1°C) with a 12/12 hour light-dark
cycle. Food and water were freely available. Only data
obtained from rats with an inferior alveolar nerve injury
caused by mal-positioned dental implants were utilized
in the final analyses. Behavioral responses were measured
in a blind fashion.
Evaluation of mechanical allodynia
For behavioral observations, each rat was placed in a
customized observation cage in a darkened and noise-
free room and the animals were acclimated for at least
30 min. An evaluation of withdrawal behavioral
responses was performed after the application of 10 suc-
cessive trials of constant air-puff pressure (4 sec
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Page 8 of 11duration, 10 sec intervals) on freely moving rats as
described previously [10,36,37]. The responses observed
included escape from air-puff stimulation, aggressive
behavior, and biting. The intensity and intervals of the
air-puff pressure was controlled with a pneumatic pump
module (BH2 system; Harvard Apparatus MA). The air-
puffs were applied through a 26-gauge metal tube
(length, 10 cm) located 1 cm from the skin at a 90°
angle. The air-puff thresholds were determined as the
air-puff pressure at which each rat responded in 50% of
the trials. The cut-off pressure for the air-puffs was 40
psi. Naïve animals did not respond to a pressure of less
than 40 psi.
Immunohistochemical staining
The rats (n = 3 per group) were transcardially perfused
with 0.9% saline, followed by 4% paraformaldehyde in
phosphate buffer (0.1 M PB, pH 7.4) on POD 3, 7, and
21. The caudal medullae was dissected out, postfixed in
the same fixative at 4°C overnight, and then replaced
with 30% sucrose in 0.1 M PB overnight. These tissue
samples were then frozen, cut in transverse sections at a
30 μm thickness, and blocked with 5% goat serum in PBS
containing 0.2% Triton X-100 for 1 h at room tempera-
ture. Subsequently, the specimens were incubated at 4°C
overnight with rabbit polyclonal anti-p-p38 MAPK
(1:400; Cell Signaling Technology, Danvers, MA) and p-
NF-B (1:400, Cell Signaling Technology, Danvers, MA)
antibodies. The sections were subsequently incubated
with Alexa 555-conjugated rabbit IgG antibody (1:200,
Invitrogen, Carlsbad, CA) for 2 h at room temperature.
For double immunofluorescence staining, the sections
were incubated with a mixture of p-p38 MAPK or p-NF-
B antibodies with the NeuN, neuronal marker (1:600;
Millipore, Temecula, CA), the OX42, microglial marker
(1:100, Millipore), or GFAP, astrocytic marker (1:1000;
Cell Signaling Technology) overnight at 4°C. This was
followed by incubation with a mixture of Alexa 555-con-
jugated rabbit IgG and Alexa 488-conjugated mouse IgG
(1:200; Invitrogen). The stained sections were observed
w i t haf l u o r e s c e n c em i c r o s c o p e( B X4 1a n dU - R F L - T ;
Olympus, Tokyo, Japan) and a confocal laser scanning
microscope (LSM 510; Carl Zeiss, Jena, Germany).
Western blotting
Animals (n = 5 per group) were sacrificed on POD 3,
7, and 21 by decapitation. The dorsal part of the cau-
dal medulla was then rapidly removed from each rat
and frozen in liquid nitrogen. Subsequently, these tis-
sue samples was sonicated with a Biorupture device
(Cosmo Bio., Tokyo, Japan) in a lysis buffer contain-
ing protease and a phosphatase inhibitor cocktail
(Thermo Scientific, Rockford, IL). Protein concentra-
tions in the samples were measured using a
fluorometer (Invitrogen). Total proteins (30 μg) were
separated in a 4-12% gradient NuPAGE Novex Bis-
Tris gel (Invitrogen) and transferred onto PVDF
membrane by using an iBlot Dry blotting system
(Invitrogen). The membranes were blocked with 5%
non-fat milk in TBS containing 0.1% Tween 20 for 1
h at room temperature and then incubated with p-
p38 MAPK (1:1000, Cell Signaling Technology) or p-
NF-B (1:500, Cell Signaling Technology) at 4°C over-
night. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibody (Santa Cruz Biotechnology, Santa
C r u z ,C A )w a su s e da sal o a d i n gc o n t r o lf o rt h ep -
p38 MAPK and p-NF-B signals. The blots were then
incubated with goat anti-rabbit horseradish peroxi-
dase or goat anti-mouse horseradish peroxidase for 1
h at room temperature. Membranes were developed
using the Super-signal West Femto substrate (Pierce,
Rockford, IL), and exposed to X-ray film. The ImageJ
analysis system (NIH, Bethesda, MD) was used for the
quantification of specific bands.
Drugs administration
To perform intracisternal injections, a polyethylene
tube (PE10) was implanted in anesthetized rats three
days before conducting the drug tests, as described
previously [38-40]. A limited-skin incision was made
and part of the atlanto-occipital membrane was
exposed by deflecting a part of the muscle from the
occipital bone. Using a 27-gauge needle, a tiny opening
was made in the dura and the tip of the cannula was
inserted through the opening and secured in place
with glue. The polyethylene tube was subcutaneously
led to the top of the skull and secured in place by a
stainless steel screw and dental acrylic resin. Each tube
was closed off with a steel wire to prevent leakage of
cerebrospinal fluid. We intracisternally administered
SB203580 (1 or 10 μg/10 μl), a p38 MAPK inhibitor,
or SN50 (0.2 or 2 ng/10 μl), a NF-Bi n h i b i t o r ,o n
POD 3 and 21, respectively. After these injections, we
evaluated the effects of SB203580 or SN50 on mechan-
ical allodynia in rats with a mal-positioned dental
implant. To investigate the antinociceptive mechanisms
of dexamethasone, we examined the expression of p-
p38 MAPK or p-NF-B after dexamethasone (25 mg/
kg) or vehicle (saline) was intraperitoneally adminis-
tered daily for three days beginning on POD 1.
SB203580 and SN50 were purchased from Calbiochem
and dexamethasone was purchased from Sigma.
SB203580 was diluted in 70% DMSO. SN50 and dexa-
methasone were diluted in sterile saline.
Data analysis
Differences between groups were compared using analy-
sis of repeated measures ANOVA followed by LSD post
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Page 9 of 11hoc analysis. Comparisons between two means were
performed with a Student’s t-test. In all statistical com-
parisons, P < 0.05 was used as the criterion for statistical
significance. All data are presented as the mean ± SEM.
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phospho-nuclear factor- kappa B; IL-1β: interleukin-1 beta; IL6: interleukin-6;
TNF-α: tumor necrosis factor-alpha; POD: postoperative day; NeuN: neuronal
nuclei; GFAP: glial fibrillary acidic protein; PB: phosphate buffer; GAPDH:
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